vTv Therapeutics has submitted a Phase 2 protocol to the Department of Health, Abu Dhabi, for cadisegliatin in insulin-treated type 2 diabetes. The 12-month, double-blind, randomized, placebo-controlled study plans to enroll roughly 300 participants across the UAE, Jordan, and Tunisia, randomizing patients to 400 mg or 800 mg once daily versus placebo as an adjunct to insulin. First-patient-in is targeted for the first quarter of 2026, and the company characterizes it as the longest clinical evaluation of the asset to date.
The immediate development is a regionally anchored, company-sponsored, but externally funded trial, designed with M42’s Insights Research Organization & Solutions (IROS), which will finance the study. At the same time, vTv serves as the regulatory sponsor. The protocol marks a formal expansion of cadisegliatin—a liver-selective glucokinase activator already in a U.S. Phase 3 program for type 1 diabetes and holding FDA Breakthrough Therapy designation in that indication—into the insulin-dependent segment of type 2 diabetes. The multicountry footprint gives vTv access to high-prevalence markets and diverse recruitment sources, helping mitigate the intensifying competition for metabolic trial participants in the U.S. and Europe.
Strategically, this is a portfolio-broadening move that hedges vTv’s T1D path with a potentially larger, but more heterogeneous, T2D population where background therapies and insulin practices vary widely. External funding lowers burn and operational risk while extending the observation window needed to assess durability, hypoglycemia liability, and potential insulin-sparing effects—key hurdles for glucokinase activators historically. The geography is also notable: Abu Dhabi’s DOH has been building a streamlined approval and oversight apparatus, and M42’s regional infrastructure can compress start-up timelines for new entrants, while positioning the program for future access discussions in the Gulf and the broader MENA region.
For sites, the design implies year-long retention demands, standardized insulin titration algorithms, and consistent background therapy management amid accelerating GLP-1/SGLT2 uptake. Expect protocol guardrails on GLP-1 receptor agonists and SGLT2 inhibitors, CGM use to capture time-in-range and hypoglycemia, and central oversight of insulin adjustments to maintain signal fidelity. Vendors supplying CGM, central labs, pharmacovigilance, and remote data review stand to benefit. At the same time, CROs will watch how the IROS-funded model reallocates budgets and decision-making between regional partners and global sponsors. Regulators will be attuned to class-specific safety—particularly hepatic enzymes and lipid changes—and whether any insulin dose reductions are achieved without increasing hypoglycemia.
The forward read-through hinges on three questions. First, can the study control real-world confounders—especially background GLP-1 therapies and variable insulin regimens—enough to demonstrate a clean A1c, time-in-range, or insulin-dose signal over 12 months? Second, will safety align with the liver-selective profile vTv is pursuing, given prior GKA class challenges, and will hypoglycemia rates remain acceptable in an insulin-treated T2D cohort? Third, how will any positive data integrate with the ongoing U.S. T1D program and potential regulatory bridges to the FDA/EMA if the initial evidence is generated in MENA? With the first patient expected in early 2026 and a one-year treatment period, the topline readout would likely land in 2027, setting the timeline for any partnering or regional commercialization moves. Watch for the final posted protocol, inclusion/exclusion details on concomitant therapies, insulin management algorithms, and the degree of CGM deployment—each will signal how aggressively vTv is positioning this study to produce decision-grade data for both regulators and potential commercial partners.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
